rosiglitazone has been researched along with Dermatitis, Atopic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, H; Jee, Y; Jung, K; Karasawa, K; Matsuda, A; Matsuda, H; Ohmori, K; Oida, K; Okamoto, N; Shin, T; Tanaka, A | 1 |
| Behshad, R; Cooper, KD; Korman, NJ | 1 |
2 other study(ies) available for rosiglitazone and Dermatitis, Atopic
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice.
Topics: Animals; Cell Movement; Cytokines; Dendritic Cells; Dermatitis, Atopic; Matrix Metalloproteinase 9; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thymic Stromal Lymphopoietin | 2011 |
A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Allergens; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Patch Tests; Patient Satisfaction; PPAR gamma; Retrospective Studies; Risk Factors; Rosiglitazone; Sampling Studies; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2008 |